Cargando…
Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents
The interaction between tumor surface-expressed PDL1 and immune cell PD1 for the evasion of antitumor immunity is well established and is targeted by FDA-approved anti-PDL1 and anti-PD1 antibodies. Nonetheless, recent studies highlight the immunopathogenicity of tumor-intrinsic PDL1 signals that can...
Autores principales: | Murray, Clare, Galvan, Eva, Ontiveros, Carlos, Deng, Yilun, Bai, Haiyan, Padron, Alvaro Souto, Hinchee-Rodriguez, Kathryn, Garcia, Myrna G., Kornepati, Anand, Conejo-Garcia, Jose, Curiel, Tyler J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099860/ https://www.ncbi.nlm.nih.gov/pubmed/35563520 http://dx.doi.org/10.3390/ijms23095129 |
Ejemplares similares
-
421 Specific cephalosporin antibiotics deplete tumor PD-L1 to inhibit DNA damage sensing and sensitize to Chk1 inhibitors in vivo
por: Murray, Clare, et al.
Publicado: (2022) -
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023) -
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
por: Reyes, Ryan Michael, et al.
Publicado: (2021) -
Ceftazidime and cefepime antagonize 5-fluorouracil’s effect in colon cancer cells
por: Pfab, Christina, et al.
Publicado: (2022) -
UVA Radiation,
DNA Damage, and Melanoma
por: Jin, Seung-Gi, et al.
Publicado: (2022)